Effect of Continuous Positive Airway Pressure on Soluble CD40 Ligand in Patients With Obstructive Sleep Apnea Syndrome
Patient Education For Children And Adolescents
September 14, 2022The Future Of Health Care Delivery And Health Policy Discussion
September 14, 2022Effect of Continuous Positive Airway Pressure on Soluble CD40 Ligand in Patients With Obstructive Sleep Apnea Syndrome
Background:
Obstructive sleep apnea syndrome (OSAS) is an independent risk factor for atherosclerosis. CD40-CD40 ligand interaction promotes several proinflammatory mediators and plays a pivotal role in the various stages of atherosclerotic diseases. The present study examines whether CD40 ligation contributes to outcomes in patients with OSAS.
Methods:
The study population comprised OSAS patients with an apnea hypopnea index (AHI) ≥ 30 (n = 35) and control subjects (AHI < 5; n = 16). We measured serum levels of soluble CD40 ligand (sCD40L), tumor necrosis factor (TNF)-α, and hypersensitive C-reactive protein (hsCRP) before and after nasal continuous positive airway pressure (nCPAP) therapy for 3 months.
Results:
Baseline levels of sCD40L were significantly higher in patients with OSAS (6.93 ± 4.64 ng/mL) [mean ± SD] than in control subjects (3.43 ± 2.11 ng/mL, p < 0.01). Baseline levels of sCD40L positively correlated with TNF-α but not with hsCRP. The elevation of sCD40L was improved for 1 night after nCPAP therapy (3.83 ± 2.78 ng/mL, p < 0.001). Even though patients with severe OSAS did not receive any other medication to control atherosclerotic risk factors for 3 months, nCPAP was continued to reduce the levels of sCD40L.
Conclusion:
The present study suggested that sCD40L is a key factor that links OSAS and atherosclerotic progression.